Citations

Showing 10 of 108094 citations.

Cardiovascular Diseases Risk Predictors: ABO Blood Groups in a Different Role
Rezaei, Abbas , Farid, Armita , Javanshir, Salar , Niri, Fatemeh Dehghan , Daneii, Padideh , Korani, Setayesh Sotoudehnia , Sotoudehnia Korani, Setayesh, Sotoudehnia, Setayesh , Neshat, Sina , Heshmat‐Ghahdarijani, Kiyan

Mayo Clinic

Cardiology in Review | June 9, 2022 | Volume: 32 | Issue: 2 | Pages: 174-179

10.1097/crd.0000000000000463 | PMID 35679024 Get It

Cardiovascular diseases (CVDs) pose a serious threat to people’s health, with extremely high global morbidity, mortality, and disability rates. This study aimed to review the literature that examined the relationship between blood groups and CVD. Many studies have reported that non-O blood groups are associated with an increased risk and severity of coronary artery disease and acute coronary syndromes. Non-O blood groups increase the risk and severity of these conditions by increasing von Willebrand factor and plasma cholesterol levels and inducing endothelial dysfunction and inflammation. They have also been linked with increased coronary artery calcification, coronary lesion complexity, and poor collateral circulation. Blood groups also affect the prognosis of coronary artery disease and acute coronary syndrome and can alter the rate of complications and mortality. Several cardiovascular complications have been described for coronavirus disease 2019, and blood groups can influence their occurrence. No studies have found a significant relationship between the Lewis blood group and CVD. In conclusion, people with non-O blood groups should be vigilantly monitored for cardiovascular risk factors as prevention and proper treatment of these risk factors may mitigate their risk of CVD and adverse cardiovascular events.
Mitochondrial adaptations to inactivity in diaphragm muscle fibers
Brown, Alyssa , Fogarty, Matthew J. , Davis, Leah A., Dasgupta, Debanjali , Sieck, Gary C. , Brown, Alyssa D , Sieck, Gary , Dasgupta, Debanjali , Fogarty, Matthew J , Mantilla, Carlos B.

Mayo Clinic

Journal of Applied Physiology | June 9, 2022 | Volume: 133 | Issue: 1 | Pages: 191-204

10.1152/japplphysiol.00090.2022 | PMID 35678745 Get It

Two weeks of diaphragm (DIAm) inactivity imposed by C2SH caused reduced mitochondrial volume density, mitochondrial fragmentation, and a concomitant reduction of SDH max in type I and IIa DIAm fibers on the lesioned side. Type I and IIa DIAm fibers were far more sensitive to inactivation than type IIx/IIb fibers, which exhibited little pathology. Our results indicate that mitochondria in DIAm fibers are plastic in response to varying levels of activity.
Proceedings of the 26th Annual Virtual Congress of the International Liver Transplantation Society
Kalisvaart, Marit , Martin, Eléonora De , Alconchel, Felipe , Keskin, Onur , Mazzola, Alessandra , Spiro, Michael , Tanaka, Tomohiro , Campos‐Varela, Isabel , Victor, David W. , Vinaixa, Carmen , Yoon, Uzung , Yoon, Young-in, Hessheimer, Amelia J. , Kabaçam, Gökhan , Shaker, Tamer , Chan, Albert , Kirchner, Varvara A. , Alconchel, Felipe , Kirchner, Varvara , Chan, Albert C Y , Chadha, Ryan , Goldaracena, Nicolás , Liu, Jiang , Nasralla, David , Rammohan, Ashwin , Yoon, Young-in, Sapisochín, Gonzalo , Bhangui, Prashant

Mayo Clinic

Transplantation | June 9, 2022 | Volume: 106 | Issue: 9 | Pages: 1738-1744

10.1097/tp.0000000000004183 | PMID 35676871 Get It

After a 1-y absence due to the coronavirus disease 2019 pandemic, the 26th Annual Congress of the International Liver Transplantation Society was held from May 15 to 18, 2021, in a virtual format. Clinicians and researchers from all over the world came together to share their knowledge on all the aspects of liver transplantation (LT). Apart from a focus on LT in times of coronavirus disease 2019, featured topics of this year’s conference included infectious diseases in LT, living donation, machine perfusion, oncology, predictive scoring systems and updates in anesthesia/critical care, immunology, radiology, pathology, and pediatrics. This report presents highlights from invited lectures and a review of the select abstracts. The aim of this report, generated by the Vanguard Committee of International Liver Transplantation Society, is to provide a summary of the most recent developments in clinical practice and research in LT.
Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA presenting as myeloid sarcoma
Barouqa, Mohammad , Hoyer, James D., Reichard, Kaaren K. , Greipp, Patricia Theresa, Hoyer, James, Jevremović, Dragan , Greipp, Patricia T. , McPhail, Ellen Darcy

Mayo Clinic

eJHaem | June 9, 2022 | Volume: 3 | Issue: 3 | Pages: 1068-1069

10.1002/jha2.477 | PMID 36051048 Get It

Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men
Chiang, Chia‐Chun , Chhabra, Nikita , Chao, Chieh‐Ju , Wang, Han , Zhang, Nan , Lim, Elisabeth S. , Baez‐Suarez, Abraham, Attia, Zachi I. , Schwedt, Todd J. , Dodick, David W. , Cutrer, F. Michael , Friedman, Paul A. , Lim, Elisabeth, Cutrer, Fred Michael , Noseworthy, Peter A , Dodick, David W , Chiang, Chia-Chun , Schwedt, Todd J , Attia, Zachi I , Chao, Chieh-Ju , Wang, Han , Noseworthy, Peter A.

Mayo Clinic

Headache: The Journal of Head and Face Pain | June 9, 2022 | Volume: 62 | Issue: 8 | Pages: 939-951

10.1111/head.14339 | PMID 35676887 Get It

Abstract Objective To compare the artificial intelligence‐enabled electrocardiogram (AI‐ECG) atrial fibrillation (AF) prediction model output in patients with migraine with aura (MwA) and migraine without aura (MwoA). Background MwA is associated with an approximately twofold risk of ischemic stroke. Longitudinal cohort studies showed that patients with MwA have a higher incidence of developing AF compared to those with MwoA. The Mayo Clinic Cardiology team developed an AI‐ECG algorithm that calculates the probability of concurrent paroxysmal or impending AF in ECGs with normal sinus rhythm (NSR). Methods Adult patients with an MwA or MwoA diagnosis and at least one NSR ECG within the past 20 years at Mayo Clinic were identified. Patients with an ECG‐confirmed diagnosis of AF were excluded. For each patient, the ECG with the highest AF prediction model output was used as the index ECG. Comparisons between MwA and MwoA were conducted in the overall group (including men and women of all ages), women only, and men only in each age range (18 to <35, 35 to <55, 55 to <75, ≥75 years), and adjusted for age, sex, and six common vascular comorbidities that increase risk for AF. Results The final analysis of our cross‐sectional study included 40,002 patients (17,840 with MwA, 22,162 with MwoA). The mean (SD) age at the index ECG was 48.2 (16.0) years for MwA and 45.9 (15.0) years for MwoA ( p < 0.001). The AF prediction model output was significantly higher in the MwA group compared to MwoA (mean [SD] 7.3% [15.0%] vs. 5.6% [12.4%], mean difference [95% CI] 1.7% [1.5%, 2.0%], p < 0.001). After adjusting for vascular comorbidities, the difference between MwA and MwoA remained significant in the overall group (least square means of difference [95% CI] 0.7% [0.4%, 0.9%], p < 0.001), 18 to <35 (0.4% [0.1%, 0.7%], p = 0.022), and 35 to <55 (0.5% [0.2%, 0.8%], p < 0.001), women of all ages (0.6% [0.3%, 0.8%], p < 0.001), men of all ages (1.0% [0.4%, 1.6%], p = 0.002), women 35 to <55 (0.6% [0.3%, 0.9%], p < 0.001), and men 18 to <35 (1.2% [0.3%, 2.1%], p = 0.008). Conclusions Utilizing a novel AI‐ECG algorithm on a large group of patients, we demonstrated that patients with MwA have a significantly higher AF prediction model output, implying a higher probability of concurrent paroxysmal or impending AF, compared to MwoA in both women and men. Our results suggest that MwA is an independent risk factor for AF, especially in patients <55 years old, and that AF‐mediated cardioembolism may play a role in the migraine–stroke association for some patients.
Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).
Lazaryan, Aleksandr , Hernandez‐Ilizaliturri, Francisco J. , Geethakumari, Praveen Ramakrishnan , Shune, Leyla , Reeder, Craig B. , Atherton, Pamela J. , Fiskum, Jack, Adjei, Alex A. , Ansell, Stephen M. , Villasboas, José C. , Kline, Justin Paul , Bartlett, Nancy L. , Awan, Farrukh T. , Karmali, Reem , Lansigan, Frederick , Diefenbach, Catherine , Sharon, Elad , Yin, Jun

Mayo Clinic

Journal of Clinical Oncology | June 8, 2022 | Volume: 40 | Issue: 17_suppl | Pages: LBA7564-LBA7564

10.1200/jco.2022.40.17_suppl.lba7564 Get It

LBA7564 Background: Patients with r/r B-NHL have a dismal prognosis. DIAL (Dual Immunomodulation in Aggressive Lymphoma) was a multi-center randomized phase II study testing the efficacy of nivolumab (PD-1 inhibitor) plus varlilumab (CD27 agonist) in this population. Methods: Patients were randomized (1:1) to nivolumab (240 mg IV every 2 weeks for 4 months, 480 mg IV monthly thereafter; group 1) alone or combined with varlilumab (3 mg/kg IV monthly; group 2). Cross-over (group 1 to 2) was allowed for progression. Primary endpoint was overall response (ORR) per LYRIC criteria. A sample size of 48 patients per arm would provide 80% power to detect increase in ORR from 25% to 45% using a one-sided test (p = 0.15). Pre-specified interim analysis occurred after half of the patients completed first radiologic assessment. Secondary endpoints included overall survival (OS), progression-free survival (PFS), and adverse events (AEs). Exploratory endpoints included tumor genomic assessment and immune profiling of blood and tumor. Results: 53 patients were enrolled (27 in group 1; 26 in group 2). Interim analysis included 24 patients from each arm. Mean age was 65.2 years, 34 (70.8%) were male, and 36 (75%) received prior CAR-T cell therapy. Baseline characteristics were balanced between arms. Grade ≥ 3 AEs were observed in 8 (33.3%) and 7 (30.4%) of patients in groups 1 and 2, respectively. Common AEs (> 5%) of any grade included fatigue, lymphopenia, diarrhea, rash. There were no treatment-associated deaths. Toxicity profile was similar between arms. Table summarizes efficacy outcomes. ORR was achieved in 6 patients (12.5%), not statistically different between arms; 4 responses were complete. Seven patients crossed over (1 responded after crossing). Median OS (8.6 vs 7.3 months; p = 0.39) and PFS (2.7 vs 1.4 months; p = 0.06) were similar between arms. Subgroup analysis of patients with prior CAR-T cell therapy showed similar ORR (5/36; 14%), not statistically different between arms. Correlative analysis results will be presented at conference. The trial met futility criterion on interim analysis and enrollment ceased based on pre-specified stopping rule. Conclusions: Dual immunomodulatory therapy did not enhance anti-tumor activity in patients with aggressive B-NHL compared to nivolumab alone. Response rates were low and consistent with previous data using PD-1 inhibitors in this population. Prior therapy with CAR-T cell does not seem to sensitize patients to PD-1 blockade. Toxicity profile was acceptable and dual therapy did not increase the rate of AEs. Clinical trial information: NCT03038672. [Table: see text]
MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic Schwannoma
Li, Jing , Sankar, Neil , Espiritu, Lynn, Redkar, Sanjeev, Yu, Guoliang , Kizilbash, Sani H. , LI, JENNY J., Sankar, Neil , Kizilbash, Sani H , Zhang, Xiaoling

Mayo Clinic

JCO Precision Oncology | June 8, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.22.00096 | PMID 35675576 Get It

Characterizing mechanism-based pain phenotypes in patients with chronic pancreatitis: a cross-sectional analysis of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies
Saloman, Jami L. , Conwell, Darwin L. , Fogel, Evan L. , Vege, Santhi Swaroop , Li, Liang , Andersen, Dana K. , Fisher, William E., Forsmark, Christopher E., Hart, Phil A. , Park, Walter G. , Topazian, Mark , Yadav, Dhiraj , Saloman, Jami L , Li, Shuang , Pandol, Stephen J. , Phillips, Anna Evans , Van Den Eeden, Stephen K , Serrano, José

Mayo Clinic

Pain | June 8, 2022 | Volume: 164 | Issue: 2 | Pages: 375-384

10.1097/j.pain.0000000000002710 | PMID 36149018 Get It

Abstract Pain is common in chronic pancreatitis (CP) and profoundly reduces quality of life (QoL). Multiple underlying mechanisms contribute to a heterogenous pain experience and reduce efficacy of pain management. This study was designed to characterize the distribution of mechanism-based pain phenotypes in painful CP. The data analyzed were collected as part of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies, an NCI/NIDDK-funded longitudinal study of the natural history of CP. The PROspective Evaluation of Chronic pancreatitis for EpidEmiologic and translational stuDies includes patient-reported outcome (PRO) measures of pain, medication use, global health, and QoL. Of subjects (N = 681) with CP, 80% experienced abdominal pain within the year before enrollment. Subjects who experienced pain in the week before enrollment (N = 391) completed PROMIS Neuropathic and Nociceptive Pain Quality instruments which were then used to classify them by pain type: 40% had nociceptive, 5% had neuropathic-like, and 32% had both types of pain. The prevalence of having both types of pain was higher among women and subjects with diabetes mellitus, whereas nociceptive-only pain was more prevalent among men and those with pancreatic duct stricture. Other factors, including pain medication use and healthcare utilization, did not differ between groups based on pain type. Subjects in the Both group had significantly worse health and QoL scores relative to those with nociceptive-only pain, suggesting that using psychosocial pain surveys may be useful for understanding pain subtypes in patients with CP. Additional research is needed to identify biochemical and biophysical signatures that may associate with and predict responses to mechanism-specific interventions.
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
Mody, Kabir , Jain, Prerna , El-Refai, Sherif , Azad, Nilofer S. , Baretti, Marina , Shroff, Rachna T. , Kelley, Robin Katie, El-Khouiery, Anthony, Hockenberry, Adam J. , Lau, Denise , El-Khoueiry, Anthony B. , El-Refai, Sherif M , Baretti, Marina , Shroff, Rachna T , Kelley, R Katie , El-Khouiery, Anthony B , Hockenberry, Adam J , Yarchoan, Mark , Zabransky, Daniel J. , Kelley, Robin Kate , Lesinski, Gregory B , Yarchoan, Mark

Mayo Clinic

JCO Precision Oncology | June 8, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00510 | PMID 35675577 Get It

PURPOSE Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and molecularly defined subsets of BTC may improve patient selection for immunotherapy and inform immune-based combination treatment strategies. METHODS We analyzed deidentified clinical, genomic, and transcriptomic data from the Tempus database to determine the mutational frequency and mutational clustering across the three major BTC subtypes (intrahepatic cholangiocarcinoma [IHC], extrahepatic cholangiocarcinoma, and gallbladder cancer). We subsequently determined the relationship between specific molecular alterations and anatomical subsets and features of the BTC immune microenvironment. RESULTS We analyzed 454 samples of BTC, of which the most commonly detected alterations were TP53 (42.5%), CDKN2A (23.4%), ARID1A (19.6%), BAP1 (15.5%), KRAS (15%), CDKN2B (14.2%), PBRM1 (11.7%), IDH1 (11.7%), TERT (8.4%), KMT2C (10.4%) and LRP1B (8.4%), and FGFR2 fusions (8.7%). Potentially actionable molecular alterations were identified in 30.5% of BTCs including 39.1% of IHC. Integrative cluster analysis revealed four distinct molecular clusters, with cluster 4 predominately associated with FGFR2 rearrangements and BAP1 mutations in IHC. Immune-related biomarkers indicative of an inflamed tumor-immune microenvironment were elevated in gallbladder cancers and in cluster 1, which was enriched for TP53, KRAS, and ATM mutations. Multiple common driver genes, including TP53, FGFR2, IDH1, TERT, BRAF, and BAP1, were individually associated with unique BTC immune microenvironments. CONCLUSION BTC subtypes exhibit diverse DNA alterations, RNA inflammatory signatures, and immune biomarkers. The association between specific BTC anatomical subsets, molecular alterations, and immunophenotypes highlights new opportunities for therapeutic development.
Polarization-Sensitive Endobronchial Optical Coherence Tomography for Microscopic Imaging of Fibrosis in Interstitial Lung Disease
Nandy, Sreyankar , Berigei, S.R., Keyes, Colleen , Muniappan, Ashok , Auchincloss, Hugh, Roop, Benjamin W., Shih, Angela , Colby, Thomas V. , Suter, Melissa J., Nandy, Sreyankar , Lanuti, Michael D. , Medoff, Benjamin D. , Villiger, Martin , Hariri, Lida P. , Shih, Angela

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 8, 2022 | Volume: 206 | Issue: 7 | Pages: 905-910

10.1164/rccm.202112-2832le | PMID 35675552 Get It